Cas:602-60-8 9-Nitroanthracene manufacturer & supplier

We serve Chemical Name:9-Nitroanthracene CAS:602-60-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

9-Nitroanthracene

Chemical Name:9-Nitroanthracene
CAS.NO:602-60-8
Synonyms:EINECS 210-021-9;MFCD00001248;Anthracene, 9-nitro-;9-Nitroanthracene
Molecular Formula:C14H9NO2
Molecular Weight:223.227
HS Code:

Physical and Chemical Properties:
Melting point:144-144ºC
Boiling point:402.9±14.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.742
PSA:45.82000
Exact Mass:223.063324
LogP:4.41

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like EINECS 210-021-9 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,9-Nitroanthracene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 210-021-9 Use and application,MFCD00001248 technical grade,usp/ep/jp grade.


Related News: GlaxoSmithKline��s HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection. 9-Nitroanthracene manufacturer United Airlines — which announced that it will suspend flights to Beijing, Chengdu and Shanghai from February 6 — is also reducing flights from the US to Hong Kong. 9-Nitroanthracene supplier Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). 9-Nitroanthracene vendor The risk-based score generated by the tool helps sponsors gain advance understanding of the appropriate level of clinical supply management oversight needed to help get their project started on time and maintain momentum as the study progresses. 9-Nitroanthracene factory Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent).